Literature DB >> 31821718

Challenging scenarios in nontuberculous mycobacterial infection in cystic fibrosis.

Stacey L Martiniano1, Charles R Esther2, Charles S Haworth3, Shannon H Kasperbauer4,5, Edith T Zemanick1, Lindsay J Caverly6.   

Abstract

This review summarizes the discussion of a session held during the 2018 North American Cystic Fibrosis (CF) Conference titled "Challenging Cases in Nontuberculous Mycobacterial (NTM) Management." In this session, a multidisciplinary panel of NTM experts discussed clinical challenges related to the management of NTM infection in people with CF in which decision-making falls outside of the Cystic Fibrosis Foundation/European Cystic Fibrosis Society NTM guidelines. Topics discussed included managing newly acquired NTM infection, selecting and monitoring treatment regimens, determining treatment endpoints, and caring for patients after NTM treatment.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  Mycobacterium abscessus complex; Mycobacterium avium complex; cystic fibrosis; nontuberculous mycobacteria

Mesh:

Year:  2019        PMID: 31821718      PMCID: PMC6980303          DOI: 10.1002/ppul.24604

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  9 in total

Review 1.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

2.  Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis.

Authors:  Stacey L Martiniano; Marci K Sontag; Charles L Daley; Jerry A Nick; Scott D Sagel
Journal:  Ann Am Thorac Soc       Date:  2014-01

3.  Detection of Mycobacterium abscessus from deep pharyngeal swabs in cystic fibrosis.

Authors:  Charles R Esther; Alan Kerr; Peter H Gilligan
Journal:  Infect Control Hosp Epidemiol       Date:  2015-03-02       Impact factor: 3.254

4.  Sputum induction improves detection of pathogens in children with cystic fibrosis.

Authors:  Jordana E Hoppe; Elinor Towler; Brandie D Wagner; Frank J Accurso; Scott D Sagel; Edith T Zemanick
Journal:  Pediatr Pulmonol       Date:  2015-01-07

5.  Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease.

Authors:  Kenneth N Olivier; David J Weber; Ji-Hyun Lee; Allison Handler; Gail Tudor; Paul L Molina; Joseph Tomashefski; Michael R Knowles
Journal:  Am J Respir Crit Care Med       Date:  2002-11-14       Impact factor: 21.405

6.  Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease.

Authors:  M Gilljam; S E Berning; C A Peloquin; B Strandvik; L O Larsson
Journal:  Eur Respir J       Date:  1999-08       Impact factor: 16.671

7.  Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer.

Authors:  Jennifer S Guimbellot; Edward P Acosta; Steven M Rowe
Journal:  Pediatr Pulmonol       Date:  2018-02-28

8.  US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis.

Authors:  R Andres Floto; Kenneth N Olivier; Lisa Saiman; Charles L Daley; Jean-Louis Herrmann; Jerry A Nick; Peadar G Noone; Diana Bilton; Paul Corris; Ronald L Gibson; Sarah E Hempstead; Karsten Koetz; Kathryn A Sabadosa; Isabelle Sermet-Gaudelus; Alan R Smyth; Jakko van Ingen; Richard J Wallace; Kevin L Winthrop; Bruce C Marshall; Charles S Haworth
Journal:  Thorax       Date:  2016-01       Impact factor: 9.139

9.  The CF-Sputum Induction Trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial.

Authors:  Katherine Ronchetti; Jo-Dee Tame; Christopher Paisey; Lena P Thia; Iolo Doull; Robin Howe; Eshwar Mahenthiralingam; Julian T Forton
Journal:  Lancet Respir Med       Date:  2018-05-16       Impact factor: 30.700

  9 in total
  2 in total

1.  Cystic fibrosis airway microbiota associated with outcomes of nontuberculous mycobacterial infection.

Authors:  Lindsay J Caverly; Madsen Zimbric; Michelle Azar; Kristopher Opron; John J LiPuma
Journal:  ERJ Open Res       Date:  2021-04-19

Review 2.  Host Immune-Metabolic Adaptations Upon Mycobacterial Infections and Associated Co-Morbidities.

Authors:  Alba Llibre; Martin Dedicoat; Julie G Burel; Caroline Demangel; Matthew K O'Shea; Claudio Mauro
Journal:  Front Immunol       Date:  2021-09-23       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.